These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15212723)

  • 1. Cost-effectiveness in Preventive Cardiology.
    Weintraub WS
    Curr Treat Options Cardiovasc Med; 2004 Aug; 6(4):279-290. PubMed ID: 15212723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country--the case of Tanzania.
    Robberstad B; Hemed Y; Norheim OF
    Cost Eff Resour Alloc; 2007 Feb; 5():3. PubMed ID: 17316431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of coronary heart disease prevention strategies in adults.
    Brown AD; Garber AM
    Pharmacoeconomics; 1998 Jul; 14(1):27-48. PubMed ID: 10182193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study.
    Ngalesoni FN; Ruhago GM; Mori AT; Robberstad B; Norheim OF
    BMC Health Serv Res; 2016 May; 16():185. PubMed ID: 27184802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries.
    Li X; Willem L; Antillon M; Bilcke J; Jit M; Beutels P
    BMC Med; 2020 Apr; 18(1):82. PubMed ID: 32248817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expert consensus (SBC/SBHCI) on the use of drug-eluting stents: recommendations of the Brazilian society of interventional cardiology/ Brazilian society of cardiology for the Brazilian public single healthcare system.
    Lima VC; Mattos LA; Caramori PR; Perin MA; Mangione JA; Machado BM; Coelho WM; Bueno RR
    Arq Bras Cardiol; 2006 Oct; 87(4):e162-7. PubMed ID: 17128305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia.
    Mould-Quevedo JF; Gutiérrez-Ardila MV; Ordóñez Molina JE; Pinsky B; Vargas Zea N
    Value Health Reg Issues; 2014 Dec; 5():48-57. PubMed ID: 29702787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis and policy choices: investing in health systems.
    Murray CJ; Kreuser J; Whang W
    Bull World Health Organ; 1994; 72(4):663-74. PubMed ID: 7923545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study.
    Lin JK; Moran AE; Bibbins-Domingo K; Falase B; Pedroza Tobias A; Mandke CN; Kazi DS
    Lancet Glob Health; 2019 Oct; 7(10):e1346-e1358. PubMed ID: 31477544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A model for undertaking effectiveness and cost-effectiveness analyses of primary preventive strategies in cardiovascular disease.
    Liew D; Lim SS; Bertram M; McNeil JJ; Vos T
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):515-22. PubMed ID: 16874139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease.
    Jacobson TA
    Curr Opin Lipidol; 1997 Dec; 8(6):369-74. PubMed ID: 9412778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation.
    Green C; Colquitt JL; Kirby J; Davidson P; Payne E
    Health Technol Assess; 2004 Nov; 8(47):iii,iv, 1-120. PubMed ID: 15527669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Established and emerging cardiovascular risk factors.
    Wood D;
    Am Heart J; 2001 Feb; 141(2 Suppl):S49-57. PubMed ID: 11174359
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.